Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide 2.4 mg) typically begins to influence appetite within the first one to two weeks of treatment, though most people notice meaningful weight loss from around week four onwards. In the STEP 1 trial, published in the New England Journal of Medicine, participants lost an average of around 15% of body weight over 68 weeks — but that result built gradually, not overnight. These are prescription-only medicines; a GPhC-registered prescriber reviews every consultation before treatment begins, because suitability is a clinical decision, not a self-assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide starts working on GLP-1 receptors almost immediately after the first injection, slowing how quickly food leaves your stomach and reducing the hunger signals your brain receives. In practice, many people describe a quieter appetite within the first week, portions feel like enough sooner, and the urge to snack between meals fades. That said, the starting dose (0.25 mg) is set for tolerability, not maximum effect; its job is to help your system adjust rather than to drive rapid weight loss from day one. You can read more about how the medicine works on the Wegovy treatment overview.
Side effects, if they appear, tend to cluster in these early weeks too. Nausea, loose stools or indigestion are the most common, usually mild and settling within a week or two of each dose step. The NHS semaglutide page sets out what to watch for and when to contact a clinician.
The honest answer for week one is: you may feel different before you look different. That is not a sign the medicine is not working.
For most people, the scales start moving meaningfully around weeks four to eight. This coincides with the first or second dose increase, by that point many patients are on 0.5 mg or 1.0 mg and the appetite-reducing effect is building. The STEP 1 trial, which tracked 1,961 adults over 68 weeks, showed a clear downward trend from the early weeks that steepened as doses increased toward the 2.4 mg maintenance level.
It is worth keeping a realistic frame around those early numbers: a kilogram or two in month one is entirely normal and is not the same as the medicine not working. If you are curious about how soon Wegovy will start working for appetite and weight, the answer depends on dose stage and individual response, but changes are rarely instant. A question our prescribers hear regularly is whether a slow start means the treatment is failing, it almost never does at this stage.
If you are considering starting treatment, our free consultation is the first step; a prescriber reviews every application the same day.
The maintenance dose of 2.4 mg is typically reached after roughly five months of gradual titration. Trial data shows weight loss continuing well beyond that point, the STEP 1 trial ran to 68 weeks and participants were still losing weight at the end, suggesting the peak effect is not hit quickly. The newer 7.2 mg dose, approved by the MHRA in April 2026, produced around 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide results. For context on where Wegovy sits against other licensed options, the weight-loss treatment overview sets out the landscape.
NICE's guidance on semaglutide (TA875) includes a review point at six months on the maintenance dose: if less than 5% of body weight has been lost by then, continuing may not be the right course. That review happens with your prescriber, not unilaterally. Details of what NICE recommends are in the TA875 guidance.
For a deeper look at the timing question from a slightly different angle, this related page on when Wegovy starts working covers what to expect at each dose step.
A plateau is not unusual and does not automatically mean Wegovy has stopped being effective. Body weight naturally resists further reduction once a new equilibrium is approached, this is a physiological response, not a failure of willpower or the medicine. If you want a practical breakdown of how soon Wegovy starts working at each titration stage, that can help you judge whether your current response is on track. Dose titration (moving to a higher maintenance dose where clinically appropriate), reviewing food choices for protein and fibre adequacy, and increasing activity all play a role in breaking a plateau. Taking your injection on the same day each week matters too; consistency keeps steady-state blood levels stable.
If you have been on Wegovy for some time and feel stuck, the right conversation is with your prescriber. Patients sometimes find it helpful to revisit how soon Wegovy does start to work at different dose levels, as a reminder that the medicine often continues to act gradually rather than all at once. At nume, aftercare support is available seven days a week, contact the team via our support page. And if you have broader questions about semaglutide as a medicine, the semaglutide information page covers the pharmacology in plain English.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.